A 24-week, Phase IIB, Randomized, Active-controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2018
Price : $35 *
At a glance
- Drugs Daprodustat (Primary) ; Recombinant erythropoietin
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 13 Aug 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 22 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 May 2015 as reported by ClinicalTrials.gov.